Biomarkers for chronic fatigue
In the SURMOUNT-1 trial (N=2,539) of tirzepatide, GI adverse events led to treatment discontinuation in only 4.3-7.1% of participants across dose groups 21, suggesting that most side effects including those downstream of GI symptoms like cramping are manageable without stopping therapy
More specifically, the following groups are most likely to see benefit from consistent use: People with insulin resistance or metabolic risk factors Because inositol-derived molecules participate in insulin signaling, supplementation has been studied in people with insulin resistance, impaired glucose regulation, and related metabolic risk
quick approvals || Brello | $129/month | Compounded semaglutide, tirzepatide | Transparent pricing
If a compound does not fit inside a sensible recovery plan, it is not a solution